Home
Why EFUDEX®?
Indications
How EFUDEX® Works
Treatment
FAQ / What to Expect
Other Products
Links
References
For Additional Information Call:
United States 1.800.556.1937
What Should I Know About Actinic Keratoses (AKs)?
AKs first appear as small tan, brown, or reddish-brown patches. They can be as small as a few millimeters, be flat or raised, and have a white scaly top that's rough to the touch. People can have 3 to 10 times as many non-visible lesions (AKs that are under the skin's surface and are not yet visible) as they do visible ones.10

Over time, AKs multiply and form larger patches on parts of the skin that are exposed to the sun (eg, face, ears, bald scalp, hands, arms, and legs). Left untreated, these lesions can develop into squamous cell carcinoma (SCC), a dangerous form of skin cancer that can spread to other parts of your body.2

AKs on the hands and arms

What Should I Know About Superficial Basal Cell Carcinoma (sBCC)?
Nonmelanoma skin cancers are becoming more common in the United States - 80% of the cases diagnosed each year are basal cell carcinomas.9 One in 5 Americans develops some kind of skin cancer - and now young people are being diagnosed with skin cancers.3
Basal cell carcinoma is a sun-induced skin cancer most often found above the neckline, on the bridge of the nose or around the eye. The lesions appear as scaly, red, flat areas with a threadlike border. Superficial basal cell carcinoma usually occurs as multiple lesions in clusters on the skin.

Printer Friendly
Prescribing Information
  • Over 14 million prescriptions have been written for Efudex over last 30 years5
  • High success rates
IMPORTANT SAFETY INFORMATION
EFUDEX® (fluorouracil) Topical Solutions and Cream is recommended for the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Safety and efficacy in other indications have not been established.
EFUDEX is contraindicated in women who are, or may become, pregnant during therapy because of potential hazards to the fetus. Cases of miscarriage and birth defects have been reported in women who are pregnant.
The most frequent adverse events occur locally and may include itching, burning, soreness, tenderness, scaling, and swelling. Application to mucous membranes should be avoided due to the possibility of local inflammation and ulceration.
Please see complete Prescribing Information for EFUDEX.
© Valeant Pharmaceuticals International 2005  Legal and Privacy Statement
Efudex® is a registered trademark of Valeant Pharmaceuticals International